Leading and developing a multidisciplinary team delivering solid-state and particle engineering capabilities across drug development and manufacturing. Setting technical vision and capability strategy to support a diverse and evolving portfolio, while providing decision-level scientific leadership on complex CMC, developability, and manufacturability challenges. Working closely with senior stakeholders across R&D, drug substance and drug product manufacturing, analytical development, and quality to align scientific strategy with broader business objectives, while building internal platforms and external collaborations that strengthen long-term capability and innovation.
Provided scientific leadership across synthetic development programs, defining CMC strategies from crystallization through cGMP manufacturing. Led crystallization and isolation process development, supported early- and late-stage CMC decisions, and linked solid-state attributes to robust, scalable processes. Introduced advanced PAT and modelling approaches, guided external CROs and academic collaborations, and supported regulatory filings, GMP manufacturing, and cost-of-goods optimization.
I collaborated with academic teams on interdisciplinary chemical engineering research, co-taught courses, and mentored undergraduate and graduate students. I contributed to proposal writing, manuscript preparation, and peer review, and served as a guest research editor. I also co-supervised and hosted multiple PhD students, supporting their scientific and professional development.
During my PhD at KU Leuven, I developed advanced crystallization processes to address key challenges in chiral separation and solid-state control. My work combined first-principles modeling, advanced analytics, and experimental process design to improve efficiency, robustness, and scalability in pharmaceutical manufacturing.
Dissertation title: Intensified Crystallization Processes for the Separation of Enantiomers
Grade: 8.1/10 (top 10%)